Antegenes^® Breast

Using polygenic risk score technology, this test assesses a women’s risk of developing breast cancer in the next 10 years so that preventative treatment can be sought at a much earlier stage.

Enquire now Buy now

Genetic risk test for breast cancer

Antegenes® Breast assesses an individual’s risk of developing breast cancer based on the technology of polygenic risk scores. It is designed to increase survival from breast cancer through early preventative measures. Using data from 2803 genome-wide single nucleotide polymorphisms (SNPs), it provides a clinically significant assessment of the risk of developing breast cancer over the next 10 years.

The test is only suitable for women aged between 30 and 75 who do not have symptoms of breast cancer and/or have not been diagnosed with the cancer.

Why choose Antegenes® Breast?

Analyses a wider genetic profile beyond the ‘known’ genes associated with hereditary breast cancer.
Enables your customers to potentially access screening earlier than the NHS National Breast Screening programme recommends.
Provides a clinical assessment for those with or without a family history of breast cancer.
Reduces the risk of premature mortality due to breast cancer.

Diseases tested►Close tab

Breast cancer

Genes tested for►Close tab

Analyses 2803 genetic variants associated with breast cancer.

Test results►Close tab

A personalised results report will be sent to the customer and made available to their clinician* (upon the customers consent)**.

There are two possible result outcomes from this test:

A lower risk test result
An increased risk test result

Every person taking the test will be sent a clinical support video explaining what their test results mean and the next steps to take.

In the case of an increased risk result, guidance is provided on what the customer should do next. This may include talking to their clinician about earlier screening options to help reduce the risk of developing prostate cancer or seeking treatment earlier to help prevent mortality from the disease.

The results report will include the following:

Polygenic risk score: A score derived from thousands of genetic variants.
Personal risk: This shows an individual’s risk of developing the cancer tested for over the next 10 years, compared to someone of their age in the general population.
General population comparison: A number showing the average risk that someone of a similar age in the general population has of developing prostate cancer.
Relative risk: A number which compares your risk to that of the general population.

No personal medical guidance is provided in the test results report. This should be obtained from the customer’s clinician.

*Results reports are only sent to the customers clinician when a test is organised through a GP/clinic/hospital.

**No results information is shared with an employer or insurance provider.

Ordering information►Close tab

Who can order this test from Everything Genetic? Healthcare providers, employers and individuals.

Turnaround time: 4 weeks from the receipt of a sample in our laboratory.

Preferred specimen: Non-invasive simple saliva sample using Oragene OG-610.

Alternative specimen collection: None.

Delivery information: Test kits will be sent out by using a Royal Mail Tracked service, unless otherwise arranged.

Pre and post test clinical support►Close tab

Pre and post-test clinical support is a mandatory requirement for all customers taking the test.

Pre-test support is provided through a clinically guided informational video which explains:

What the test is for
Why customers should take the test
What it does and doesn’t test for
What the possible results are from taking the test

Following the test, customers will be provided a further clinically guided information video, depending on their level of risk.

In the case of an increased risk result, guidance is provided on what the customer should do next. This may include talking to their clinician about earlier screening options to help reduce the risk of developing breast cancer or seeking treatment earlier to help prevent mortality from the disease.

For both pre and post-test clinical support, the customer has the option to arrange a telephone call with our Medical Director, Dr James Mackay.

Clinical description►Close tab

The average woman has a 12% chance of developing breast cancer over her lifetime. Most cases are not inherited, but around 5%-10% of breast cancers are due to a pathogenic variant in a disease-causing gene.

This test uses data from 2803 genome-wide single nucleotide polymorphisms (SNPs) to evaluate individual polygenic risks of developing breast cancer. It combines the number of risk-increasing and lowering SNPs in the genome and their effects, which are summed up to form an overall estimate. Each SNP has little impact on the overall risk of breast cancer but combining the effects of individual SNPs contributes to a clinically significant assessment of the total risk.

Antegenes® Breast is a registered CE-marked medical device (IVD) developed by the Antegenes Medical Laboratory.

Limitations:

This test is not used to diagnose breast cancer.
An increased risk estimated by the Antegenes® Breast test does not mean that the individual will develop breast cancer during their lifetime. Also, a lower risk does not mean that the probability of developing the disease is zero.
The test does not assess the risk of family and relatives, i.e., polygenic risk score-based disease risks may not be transmitted directly from parents to children.
The test does not analyse rare pathogenic mutations in genes that significantly increase the risk of breast cancer, such as BRCA1, BRCA2, CHEK2, PALB2, ATM, TP53, CDH1, STK11, and others.